NLS Agreement

H. Lundbeck has entered into an agreement with biotech company ImmunoBrain Checkpoint for the rights to IBC’s groundbreaking research in the treatment of Alzheimer’s disease. The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease which 48 million patients are estimated to suffer from. A number […]

AstraZeneca has entered an agreement with Grünenthal for the global rights to Zomig (zolmitriptan) outside Japan. Zomig is indicated for the acute treatment of migraines and cluster headaches, an area of medicine outside AstraZeneca’s strategic focus. Grünenthal will pay AstraZeneca $200 million upon completion. AstraZeneca will also receive up to an additional $102 million in future […]

The company’s US subsidiary, Veloxis Pharmaceuticals, Inc., has entered into an exclusive license, supply and distribution agreement with Taiba Healthcare to register, commercialize and distribute Envarsus XR in certain countries throughout the Middle East and North Africa (MENA) region. Under the terms of the agreement, Veloxis will receive an up-front payment and a one-time sales […]

AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure. Recordati will pay AstraZeneca $300 million upon completion of the agreement. AstraZeneca will also receive sales-related income through […]

NNIT has signed an extension of its infrastructure outsourcing agreement with Novo Nordisk. The estimated total value of the agreement amounts to approximately DKK 1bn and covers global services, including support and maintenance of Novo Nordisk’s corporate IT infrastructure. The agreement covers Novo Nordisk’s global IT infrastructure and further supports the pharmaceutical company’s cloud strategy […]

NeuroVive Pharmaceutical and Yungjin Pharm Corporation have entered into a global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders. The in-licensed project is about to enter Phase I clinical development. KL1333 is a drug intended for treatment of orphan genetic mitochondrial disorders. KL1333 acts through modulating the levels of NAD+ and thereby […]